Skip to content

Study · Measured the body's own peptide · 1986

1 result

Circulating thymulin and thymosin-alpha 1 activity in pediatric acquired immune deficiency syndrome: in vivo and in vitro studies.

Rubinstein A, Novick BE, Sicklick MJ, Bernstein LJ, Incefy GS, Naylor PH, Goldstein AL

The Journal of pediatrics1 Sept 1986Cited by 18 (Europe PMC)

PMID3018210 (opens in a new tab)DOI10.1016/s0022-3476(86)80111-1 (opens in a new tab)PepBankPUB-03018210
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Children with AIDS or AIDS-related complex had elevated serum levels of thymosin alpha‑1 compared with patients with congenital T cell deficiencies.

    In plain wordsChildren with AIDS had higher levels of the body's own thymosin alpha‑1 in blood than children with inborn T cell deficiencies.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum thymosin alpha 1 level in pediatric AIDS
    Study

    n = 25

    Comparator
    Patients with congenital T cell deficiencies
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In contrast to patients with congenital T cell deficiencies, our patients had elevated serum levels of thymosin-alpha 1.
    1 context sentence
    Summary · context
    Twenty-five children with acquired immune deficiency syndrome (AIDS) or AIDS-related complex had a characteristic pattern of T cell deficiency.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 5Current

    21 Oct 2026, 13:55 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.